Opus Genetics, Inc. Current Liabilities
Opus Genetics, Inc. (IRD) had Current Liabilities of $7.61 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:LiabilitiesCurrent · last filed 2026-08-06
- 2026-06-30: Liabilities, Current $7.61M.
- 2026-03-31: Liabilities, Current $9.34M.
- 2025-12-31: Liabilities, Current $7.78M.
- 2025-09-30: Liabilities, Current $29.09M.
| Period end | Liabilities, Current | Liabilities, Current as first filed |
|---|---|---|
| 2026-06-30 | $7.61M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $9.34M 10-Q · filed 2026-05-12 | |
| 2025-12-31 | $7.78M 10-Q · filed 2026-08-06 | |
| 2025-09-30 | $29.09M 10-Q · filed 2025-11-12 | |
| 2025-06-30 | $20.19M 10-Q · filed 2025-08-13 | |
| 2025-03-31 | $24.25M 10-Q · filed 2025-05-15 | |
| 2024-12-31 | $11.29M 10-K · filed 2026-03-12 | |
| 2024-09-30 | $6.09M 10-Q · filed 2024-11-12 | |
| 2024-06-30 | $4.20M 10-Q · filed 2024-08-13 | |
| 2024-03-31 | $5.79M 10-Q · filed 2024-05-10 | |
| 2023-12-31 | $4.04M 10-K · filed 2025-03-31 | |
| 2023-09-30 | $3.91M 10-Q · filed 2023-11-13 | |
| 2023-06-30 | $5.76M 10-Q · filed 2023-08-11 | |
| 2023-03-31 | $4.15M 10-Q · filed 2023-05-15 | |
| 2022-12-31 | $2.75M 10-K · filed 2024-03-08 | |
| 2022-09-30 | $2.69M 10-Q · filed 2022-11-04 | |
| 2022-06-30 | $3.30M 10-Q · filed 2022-08-12 | |
| 2022-03-31 | $3.21M 10-Q · filed 2022-05-13 | |
| 2021-12-31 | $3.85M 10-K · filed 2023-03-30 | |
| 2021-09-30 | $2.64M 10-Q · filed 2021-11-12 | |
| 2021-06-30 | $2.70M 10-Q · filed 2021-08-12 | |
| 2021-03-31 | $2.31M 10-Q · filed 2021-05-07 | |
| 2020-12-31 | $3.19M 10-K · filed 2022-03-24 | |
| 2020-09-30 | $3.01M 10-Q · filed 2020-10-29 | |
| 2020-06-30 | $2.98M 10-Q · filed 2020-08-14 | |
| 2020-03-31 | $1.98M 10-Q · filed 2020-05-07 | |
| 2019-12-31 | $9.34M 10-K · filed 2021-03-11 | $2.91M 10-K · filed 2020-02-21 |
| 2019-09-30 | $3.00M 10-Q · filed 2019-11-06 | |
| 2019-06-30 | $3.55M 10-Q · filed 2019-08-07 | |
| 2019-03-31 | $2.51M 10-Q · filed 2019-05-10 | |
| 2018-12-31 | $3.15M 10-K · filed 2020-02-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |